Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

TNF inhibition for ophthalmic indications: current status and outlook.

Rifkin LM, Birnbaum AD, Goldstein DA.

BioDrugs. 2013 Aug;27(4):347-57. doi: 10.1007/s40259-013-0022-9. Review.

PMID:
23568177
2.

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.

Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17.

PMID:
24359625
3.

Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.

Borrás-Blasco J, Casterá DE, Cortes X, Abad FJ, Rosique-Robles JD, Mallench LG.

Int J Clin Pharmacol Ther. 2015 May;53(5):377-90. doi: 10.5414/CP202171. Review.

PMID:
25345430
4.

Anti-tumor necrosis factor-α therapy in uveitis.

Cordero-Coma M, Sobrin L.

Surv Ophthalmol. 2015 Nov-Dec;60(6):575-89. doi: 10.1016/j.survophthal.2015.06.004. Epub 2015 Jul 9. Review.

PMID:
26164735
5.

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis.

Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, Bardales R, Elashoff D, Vangala S, Furst DE.

BioDrugs. 2015 Aug;29(4):241-58. doi: 10.1007/s40259-015-0134-5. Review.

PMID:
26280210
6.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
7.

Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.

Galor A, Perez VL, Hammel JP, Lowder CY.

Ophthalmology. 2006 Dec;113(12):2317-23. Epub 2006 Sep 25.

PMID:
16996615
8.

Biologic therapy for refractory scleritis: a new treatment perspective.

de Fidelix TS, Vieira LA, de Freitas D, Trevisani VF.

Int Ophthalmol. 2015 Dec;35(6):903-12. doi: 10.1007/s10792-015-0124-0. Epub 2015 Aug 29. Review.

PMID:
26319144
9.

[Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].

Fery-Blanco C, Schwartz C, Gil H, Curlier E, Prati C, Delbosc B.

J Fr Ophtalmol. 2011 Dec;34(10):697-702. doi: 10.1016/j.jfo.2011.03.011. Epub 2011 Sep 1. French.

10.

Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.

Theodossiadis PG, Markomichelakis NN, Sfikakis PP.

Retina. 2007 Apr-May;27(4):399-413. Review.

PMID:
17420690
11.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.

PMID:
23032984
12.

Anti-TNF agents for paediatric psoriasis.

Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X.

Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2. Review.

PMID:
26598969
13.

New indications for treatment of chronic inflammation by TNF-alpha blockade.

Reimold AM.

Am J Med Sci. 2003 Feb;325(2):75-92.

PMID:
12589232
14.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

15.

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT.

Arch Ophthalmol. 2005 Jul;123(7):903-12.

PMID:
16009830
16.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
17.

Biologic agents in the management of inflammatory eye diseases.

Michalova K, Lim L.

Curr Allergy Asthma Rep. 2008 Jul;8(4):339-47. Review.

PMID:
18606088
18.

Immunosuppressive therapy for ocular diseases.

Jap A, Chee SP.

Curr Opin Ophthalmol. 2008 Nov;19(6):535-40. doi: 10.1097/ICU.0b013e3283126d20. Review.

PMID:
18854699
19.

Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.

Schabert VF, Bruce B, Ferrufino CF, Globe DR, Harrison DJ, Lingala B, Fries JF.

Curr Med Res Opin. 2012 Apr;28(4):569-80. doi: 10.1185/03007995.2012.656844. Epub 2012 Mar 6.

PMID:
22236091
20.

[Research update of anti-TNF-α biologic agents in the treatment of uveitis].

Fan F, Zhou M, Luo Y.

Zhonghua Yan Ke Za Zhi. 2013 Mar;49(3):285-8. Review. Chinese.

PMID:
23866712

Supplemental Content

Support Center